LOG IN
SIGN UP
MARKET
ARMP
ARMP
Armata Pharmctcl
AMEX
Real-time Quotes | Nasdaq Last Sale
4.170
-0.350
-7.74%
Closed 16:00 05/27 EDT
OPEN
4.489
PREV CLOSE
4.520
HIGH
4.520
LOW
4.170
VOLUME
1.93K
TURNOVER
5.19K
52 WEEK HIGH
6.49
52 WEEK LOW
2.820
MARKET CAP
150.59M
P/E (TTM)
-4.1671
1D
5D
1M
3M
1Y
5Y
BRIEF-Armata Pharma Doses First Patient In Phase 1B/2A Study Of Treatment Of Bacteremia Due To Staphylococcus Aureus
reuters.com · 5d ago
Armata Pharma Reports First Patient Dosed In Phase 1b/2a Study Of Co.'s AP-SA02 In Adults With Bacteremia Due To Staphylococcus Aureus
Study conducted in partnership with the US Department of Defense MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a
Benzinga · 5d ago
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the f...
PR Newswire · 5d ago
Armata Pharmaceuticals Says First Patient Dosed in Early Trial of AP-SA02 to Treat Bloodstream Infections
MT Newswires · 5d ago
Armata Pharmaceuticals Q1 EPS $(0.30) Down From $(0.27) YoY, Sales $1.24M Up From $1.07M YoY
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.30) per share. This is a 11.11 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $1.24 million in
Benzinga · 05/12 21:00
Armata Pharmaceuticals GAAP EPS of -$0.30 misses by $0.09, revenue of $1.24M beats by $0.26M
Armata Pharmaceuticals press release (NYSE:ARMP): Q1 GAAP EPS of -$0.30 misses by $0.09. Revenue of $1.24M (+15.9% Y/Y) beats by $0.26M.
Seekingalpha · 05/12 20:57
BRIEF-Armata Pharmaceuticals Announces Q1 2022 Results
reuters.com · 05/12 20:18
Executives Buy Over $30M Of 3 Stocks
Although the Nasdaq jumped more than 200 points on Monday, there were a few notable insider trades.
Benzinga · 04/04 16:33
No Data
Learn about the latest financial forecast of ARMP. Analyze the recent business situations of Armata Pharmctcl through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ARMP stock price target is 7.67 with a high estimate of 9.00 and a low estimate of 7.00.
Current 4.170
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Institutional Holdings
Institutions: 13
Institutional Holdings: 119.54K
% Owned: 0.33%
Shares Outstanding: 36.11M
TypeInstitutionsShares
Increased
4
43.82K
New
0
0
Decreased
5
147.23K
Sold Out
13
36.03K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chief Executive Officer/Director
Brian Varnum
Chief Financial Officer
Steven Martin
Vice President - Finance/Vice President - Administration
Erin Butler
Vice President - Operations
Duane Morris
Vice President
Mina Pastagia
Director
Todd Patrick
Independent Director
Jules Haimovitz
Independent Director
Odysseas Kostas
Independent Director
Robin Kramer
Independent Director
Joseph Patti
Independent Director
Todd Peterson
Independent Director
Sarah Schlesinger
No Data
No Data
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. The Company is a developer of synthetic phage platform, which targets therapeutics for the treatment of various multidrug-resistant bacterial infections. It develops synthetic phage products that target a specific pathogen begins with the isolation of natural phages from environmental and clinical samples. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AP-PA02 and AP-SA02.
Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.